Rallybio Corp Asset Resilience Ratio
Rallybio Corp asset resilience ratio. Rallybio Corp (RLYB) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Rallybio Corp (RLYB) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Rallybio Corp (2021–2025)
Asset resilience ratio of Rallybio Corp from 2021 to 2025. This chart shows how Rallybio Corp's Asset Resilience Ratio has changed over time. Read debt load of Rallybio Corp for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Rallybio Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Rallybio Corp assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Rallybio Corp maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Rallybio Corp Industry Peers by Asset Resilience Ratio
Compare Rallybio Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Rallybio Corp Asset Resilience Ratio by Year (2021–2025)
Rallybio Corp asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Rallybio Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.52% | $23.36 Million | $62.26 Million | -38.25pp |
| 2024-12-31 | 75.77% | $51.61 Million | $68.11 Million | +1.88pp |
| 2023-12-31 | 73.89% | $85.44 Million | $115.62 Million | +11.80pp |
| 2022-12-31 | 62.09% | $112.04 Million | $180.44 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $182.19 Million | -- |
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical … Read more